Sarcopenia – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Sarcopenia – Pipeline Review, H2 2019’, provides an overview of the Sarcopenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Sarcopenia

– The report reviews pipeline therapeutics for Sarcopenia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Sarcopenia therapeutics and enlists all their major and minor projects

– The report assesses Sarcopenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Sarcopenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Sarcopenia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sarcopenia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biophytis SA

Faraday Pharmaceuticals Inc

Helixmith Co Ltd

Immusoft Corp

Keren Therapeutics

MYOS RENS Technology Inc

Neurotune AG

PhaseBio Pharmaceuticals Inc

ST Pharm Co Ltd

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sarcopenia ”“ Overview

Sarcopenia ”“ Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Sarcopenia ”“ Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sarcopenia ”“ Companies Involved in Therapeutics Development

Biophytis SA

Faraday Pharmaceuticals Inc

Helixmith Co Ltd

Immusoft Corp

Keren Therapeutics

MYOS RENS Technology Inc

Neurotune AG

PhaseBio Pharmaceuticals Inc

ST Pharm Co Ltd

Teijin Pharma Ltd

Sarcopenia ”“ Drug Profiles

ARM-210 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVGN-7 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIO-101 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Muscle Wasting Disorders and Sarcopenia ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit SARM1 for Sarcopenia ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Muscular Atrophy, Sarcopenia and Traumatic Nerve Injury ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Sarcopenia ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KT-101 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KT-102 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KT-103 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-1654 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OC-501 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OC-504 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-1023 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Sarcopenia ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Sarcopenia ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit NNMT for Sarcopenia ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Cyclooxygenase 2 for Sarcopenia ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium iodide ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEISARM-2 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sarcopenia ”“ Dormant Projects

Sarcopenia ”“ Discontinued Products

Sarcopenia ”“ Product Development Milestones

Featured News & Press Releases

Oct 31, 2019: Biophytis files protocol amendment to optimize the SARA-INT phase 2b clinical trial for sarcopenia

Oct 04, 2019: Biophytis opens 22nd clinical site in the SARA-INT phase 2b trial of Sarconeos (BIO101) for the treatment of sarcopenia

Feb 18, 2019: Biophytis announces three oral and one poster presentations at the 2019 International Conference on Frailty and Sarcopenia Research

Dec 07, 2018: BIOPHYTIS announces one oral presentation and two poster presentations at the 11th international conference on cachexia, sarcopenia and muscle wasting

Nov 27, 2018: BIOPHYTIS to host Key Opinion Leader Meeting on the biology of Aging and its application in Neuromuscular Diseases

Sep 04, 2018: Biophytis provides enrollment update in its phase 2b SARA-OBS and SARA-INT studies of Sarconeos in sarcopenia

May 24, 2018: BIOPHYTIS: Inclusion of the First Patient in Phase 2b Study in Sarcopenia

Mar 01, 2018: BIOPHYTIS updates on SARA clinical study of Sarconeos in sarcopenia and presents four posters at the International Conference on Frailty & Sarcopenia Research (ICFSR) in Miami

Dec 08, 2017: Biophytis Presents 4 Posters on Sarconeos at 10th International Conference on Cachexia, Sarcopenia, and Wasting Disorders (SCWD)

Dec 04, 2017: Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium

Oct 30, 2017: BIOPHYTIS Has FDA Approval to Initiate SARA-INT Phase 2b Interventional Study of Sarconeos in Sarcopenia

Sep 25, 2017: Biophytis filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia

May 11, 2017: BIOPHYTIS: First patient-in in the United States and opening of 2 clinical centers for the SARA-OBS study on Sarcopenia

May 03, 2017: BIOPHYTIS confirms that Sarconeos modulates the Renin-Angiotensin System and activates muscular metabolism in the SARA-PK clinical trial

Mar 27, 2017: Biophytis opens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Sarcopenia, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Sarcopenia ”“ Pipeline by Biophytis SA, H2 2019

Sarcopenia ”“ Pipeline by Faraday Pharmaceuticals Inc, H2 2019

Sarcopenia ”“ Pipeline by Helixmith Co Ltd, H2 2019

Sarcopenia ”“ Pipeline by Immusoft Corp, H2 2019

Sarcopenia ”“ Pipeline by Keren Therapeutics, H2 2019

Sarcopenia ”“ Pipeline by MYOS RENS Technology Inc, H2 2019

Sarcopenia ”“ Pipeline by Neurotune AG, H2 2019

Sarcopenia ”“ Pipeline by PhaseBio Pharmaceuticals Inc, H2 2019

Sarcopenia ”“ Pipeline by ST Pharm Co Ltd, H2 2019

Sarcopenia ”“ Pipeline by Teijin Pharma Ltd, H2 2019

Sarcopenia ”“ Dormant Projects, H2 2019

Sarcopenia ”“ Dormant Projects, H2 2019 (Contd..1), H2 2019

Sarcopenia ”“ Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Sarcopenia, H2 2019 9

Number of Products under Development by Companies, H2 2019 10

Number of Products under Development by Universities/Institutes, H2 2019 12

Number of Products by Targets, H2 2019 15

Number of Products by Stage and Targets, H2 2019 15

Number of Products by Mechanism of Actions, H2 2019 17

Number of Products by Stage and Mechanism of Actions, H2 2019 17

Number of Products by Routes of Administration, H2 2019 19

Number of Products by Stage and Routes of Administration, H2 2019 19

Number of Products by Molecule Types, H2 2019 21

Number of Products by Stage and Molecule Types, H2 2019 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports